Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00468910
Other study ID # NCI-2009-00841
Secondary ID NCI-2009-00841CD
Status Active, not recruiting
Phase Phase 2
First received May 2, 2007
Last updated December 6, 2013
Start date March 2007

Study information

Verified date December 2013
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This randomized phase II trial is studying how well aspirin works in preventing colorectal cancer in patients at increased risk of colorectal cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of aspirin may prevent colorectal cancer.


Description:

PRIMARY OBJECTIVE:

I. Determine whether acetylsalicylic acid (aspirin) will alter spectral markers (i.e., spectral slope and fractal dimension) in distal colonic mucosa of patients who are at increased risk for the development or recurrence of colorectal cancer.

SECONDARY OBJECTIVES:

I. Assess the effect of this drug on colonic epithelial apoptosis and cell proliferation in these patients.

II. Assess the effect of this drug on rectal prostaglandin levels in these patients.

III. Assess the effect of this drug on platelet cyclooxygenase activity in these patients.

IV. Correlate changes in spectral markers with UGT1A6 genotype in patients treated with this drug.

OUTLINE: This is a multicenter, randomized, double-blind, placebo-controlled study. Patients are stratified by clinical site and adenoma/carcinoma maximal size. Patients with abnormal spectral biomarkers are randomized to 1 of 2 treatment arms.

ARM I: Patients receive oral acetylsalicylic acid (aspirin) once daily.

ARM II: Patients receive oral placebo once daily.

In both arms, treatment continues for 3 months in the absence of unacceptable toxicity.

Patients undergo flexible sigmoidoscopy and biopsies as well as blood collection at baseline (during prestudy colonoscopy) and at completion of study treatment for comparison of spectral signatures with biomarkers of both aspirin activity (including plasma cyclooxygenase activity and rectal prostaglandin levels) as well as with biomarkers associated with antineoplastic alteration (including apoptosis and cell proliferation). UGT1A6 genotyping analysis is also performed.

After completion of study treatment, patients are followed at 3 months.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 115
Est. completion date
Est. primary completion date December 2009
Accepts healthy volunteers No
Gender Both
Age group N/A to 75 Years
Eligibility Criteria:

- No active or metastatic cancer within the past 6 months

- Scheduled to undergo colonoscopy for colonic neoplasia surveillance

- Hemoglobin >= 12.0 g/dL

- Platelet count >= 120,000/mm^3

- AST or ALT =< 1.5 times upper limit of normal (ULN)

- Alkaline phosphatase =< 1.5 times ULN

- Bilirubin =< 1.5 times ULN

- BUN =< 40 mg/dL

- Glomerular filtration rate >= 45 mL/min

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No coagulopathy

- No anemia

- No history of peptic ulcer disease or gastrointestinal hemorrhage

- No history of cerebrovascular accident

- No uncontrolled hypertension

- No history of intolerance or allergy to aspirin or to NSAIDs

- No liver disease as manifested by signs or symptoms of cirrhosis

- No endoscopic or radiographic evidence of portal hypertension

- No active colitis by endoscopy

- No history of inflammatory bowel disease

- No requirement for aspirin as medical therapy (i.e., post-myocardial infarction or transient ischemic attack)

- No untreated helicobacter pylori infection

- History of significant colonic neoplasia, defined as 1 of the following:

- Adenoma within the past 6 years

- Colorectal cancer within the past 6 years

- Known adenoma on present exam

- Histologically confirmed polyps seen on imaging

- INR =< 1.5

- At least 6 months since prior cancer treatment

- No other concurrent acetylsalicylic acid (aspirin)-containing products or non-steroidal anti-inflammatory drugs (NSAIDs)

- No concurrent systemic corticosteroids

- No other concurrent anticoagulants or antiplatelet agents

- No concurrent investigational drugs

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention


Intervention

Drug:
acetylsalicylic acid
Given orally
placebo
Given orally
Other:
laboratory biomarker analysis
Correlative study

Locations

Country Name City State
United States Northwestern University Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in spectral slope The difference in the observed change from baseline in each arm, aspirin and placebo, will be compared. From baseline to 3 months after completion of study treatment No
Primary Change in fractal dimension The difference in the observed change from baseline in each arm, aspirin and placebo, will be compared. From baseline to 3 months after completion of study treatment No
Secondary Colonic epithelial apoptosis as measured by immunohistochemical detection of cleaved caspase 3 Up to 3 months after completion of study treatment No
Secondary Colonic cell proliferation as measured by immunohistochemical detection of Ki67 Up to 3 months after completion of study treatment No
Secondary Rectal prostaglandin levels as measured by ELISA Up to 3 months after completion of study treatment No
Secondary Platelet cyclooxygenase (COX) activity as measured by a peroxidase-based COX enzyme activity assay Up to 3 months after completion of study treatment No
See also
  Status Clinical Trial Phase
Recruiting NCT06380101 - Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC) N/A
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Recruiting NCT04323722 - Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04088955 - A Digimed Oncology PharmacoTherapy Registry
Active, not recruiting NCT01347697 - Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer N/A
Recruiting NCT04495088 - Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer Phase 3
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Terminated NCT01347645 - Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer Phase 1/Phase 2
Not yet recruiting NCT03520088 - PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS N/A
Recruiting NCT05556473 - F-Tryptophan PET/CT in Human Cancers Phase 1
Recruiting NCT04749381 - The Role of TCM on ERAS of Rectal Cancer Patients Phase 2
Enrolling by invitation NCT05028192 - Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
Recruiting NCT03283540 - Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Recruiting NCT05914766 - An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer N/A
Recruiting NCT04852653 - A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
Recruiting NCT03190941 - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Phase 1/Phase 2
Completed NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A
Terminated NCT02933944 - Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer Phase 1